NetScientific (EMVC) AI Stock Analysis

• Market Cap: £16.92M
• Dividend Yield: N/A
• Average Volume (3M): 31.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: 30.40%
• EPS Growth: 23.48%
• Country: UK
• Employees: 29
• Sector: Financial
• Sector Strength: 70
• Industry: Asset Management
• EPS (TTM): -0.04
• Shares Outstanding: 27,967,531
• 10 Day Avg. Volume: 35,929
• 30 Day Avg. Volume: 31,987
• PEG Ratio: -0.21
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 4.82
• P/FCF Ratio: -5.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: 58.00p ▼(-4.13% Downside)

The overall stock score is primarily influenced by the company's financial performance challenges, particularly in profitability and cash flow management. While technical indicators show bullish momentum, the valuation is unattractive due to negative earnings. Positive corporate events provide some optimism for future growth and strategic positioning.

Positive Factors

Revenue Growth

Strong revenue growth indicates potential for market expansion and increased demand for NetScientific's portfolio companies' innovations.

Low Leverage

Low leverage enhances financial stability, providing flexibility to invest in growth opportunities without excessive debt burden.

Equity Base

A strong equity base supports long-term growth and stability, enabling the company to withstand financial challenges and invest in its portfolio.

Negative Factors

Profitability Challenges

Ongoing profitability challenges can hinder sustainable growth and shareholder value, requiring strategic improvements in cost management.

Negative Cash Flow

Negative cash flow from operations limits the company's ability to self-fund growth and increases reliance on external financing.

Negative Returns

Negative returns on equity indicate challenges in generating shareholder value, impacting investor confidence and long-term investment appeal.

NetScientific Business Overview & Revenue Model

Company Description

EMV Capital plc is a venture capital firm specializing in seed, growth capital, early and mid stage investments. The firm focuses to invest in sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, AI and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets, United Kingdom and in the United States. It typically invests up to £15 million ($20.32 million), but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. EMV Capital plc was founded in 2008 and is based in London, United Kingdom with additional office in Beaconsfield, United Kingdom.

How the Company Makes Money

NetScientific generates revenue primarily through its investments in a diverse portfolio of life sciences companies. The company makes money by taking equity stakes in these firms, which can lead to significant returns upon successful exits through mergers, acquisitions, or public offerings. Additionally, NetScientific may earn revenue through licensing agreements and collaborations with other healthcare entities, leveraging its proprietary technologies and expertise. Strategic partnerships with industry leaders and research institutions also enhance its revenue potential by facilitating access to new markets and funding opportunities.

NetScientific Financial Statement Overview

Summary

NetScientific shows potential for revenue growth but struggles with profitability and cash flow generation. The balance sheet indicates low leverage but highlights concerns with negative returns. The company needs to improve its operational efficiency and cash flow management to sustain long-term growth.

Income Statement

NetScientific has shown revenue growth with a notable increase from the previous year (69.5% in 2023 to 2024), indicating potential for expansion. However, the company is facing challenges with profitability, as evidenced by negative EBIT and net income margins, which suggest persistent operational inefficiencies and high costs.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio is low, indicating low leverage, which is positive. However, the return on equity is negative due to consistent net losses, raising concerns about shareholder value generation. The equity ratio is strong, suggesting a solid equity base.

Cash Flow

Cash flow from operations remains negative, and free cash flow is deteriorating, reflecting liquidity constraints. Despite a positive free cash flow growth rate from 2023 to 2024, the company struggles to generate cash from operations, relying heavily on financing activities to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.36M	2.45M	1.45M	1.00M	1.11M	394.00K
Gross Profit	1.75M	2.09M	1.23M	782.00K	989.00K	348.00K
EBITDA	-2.74M	-3.12M	-2.27M	-3.31M	-2.65M	-2.20M
Net Income	-2.50M	-3.06M	-2.64M	-3.09M	-2.38M	-1.61M
Balance Sheet
Total Assets	19.65M	19.50M	22.46M	28.95M	20.69M	8.07M
Cash, Cash Equivalents and Short-Term Investments	548.00K	949.00K	347.00K	580.00K	2.35M	1.03M
Total Debt	1.49M	1.53M	2.53M	1.25M	654.00K	509.00K
Total Liabilities	6.07M	5.43M	5.35M	3.71M	2.18M	1.17M
Stockholders Equity	14.82M	15.10M	17.83M	25.84M	18.50M	6.74M
Cash Flow
Free Cash Flow	-1.45M	-1.97M	-3.51M	-3.16M	-3.54M	-2.88M
Operating Cash Flow	-1.44M	-1.78M	-3.14M	-2.56M	-3.48M	-2.79M
Investing Cash Flow	140.00K	12.00K	1.11M	-1.08M	-3.46M	-959.00K
Financing Cash Flow	1.52M	2.57M	1.39M	1.74M	8.02M	1.89M

NetScientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 60.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EMVC, the sentiment is Positive. The current price of 60.5 is above the 20-day moving average (MA) of 58.40, above the 50-day MA of 52.83, and above the 200-day MA of 47.01, indicating a bullish trend. The MACD of 1.95 indicates Positive momentum. The RSI at 82.60 is Negative, neither overbought nor oversold. The STOCH value of 78.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EMVC.

NetScientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
MAFL	65 Neutral	£16.49M	7.45	―	―	-79.36%	78.16%
EMVC	52 Neutral	£16.92M	-6.32	-14.80%	―	30.40%	23.48%
KRM	48 Neutral	£21.95M	-8.08	―	―	15.59%	54.47%
450	44 Neutral	£14.09M	-19.09	-21.85%	―	―	―
FIPP	43 Neutral	£12.10M	-1.65	-14.62%	―	-9.22%	-386.93%
TEAM	41 Neutral	£17.14M	-3.16	-36.43%	―	59.01%	-164.94%

NetScientific Corporate Events

EMV Capital Discloses PDMR Share Transfer with No Change in Beneficial Holding

EMV Capital plc has disclosed a transaction by person discharging managerial responsibilities (PDMR) Nick Salisbury, who transferred 7,000 ordinary shares from his personal brokerage account to his Self-Invested Personal Pension for portfolio consolidation purposes. The move, executed as a sale at £0.601 per share and immediate repurchase at £0.615 per share on AIM, leaves Salisbury’s beneficial holding unchanged at 72,363 shares, representing 0.26% of the company’s issued share capital, indicating no change in his economic exposure and minimal implications for overall shareholder structure.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £58.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital-backed Sofant Secures £6.25m to Pivot from R&D to Commercial Rollout

EMV Capital’s portfolio company Sofant Technologies has raised around £6.25m in a pivotal equity round that converts the bulk of its outstanding loans into shares and injects new capital to fund the shift from multi-year R&D to commercial launch and production. Led and structured by EMV Capital’s advisory arm, the deal brings in significant backing from Scottish Enterprise, the National Security Strategic Investment Fund and other investors, modestly increases EMV Capital’s direct stake and lifts the fair value of both its own holding and its third-party assets under management in Sofant, underscoring the VC’s role at a key value inflection point. The funding follows a technical breakthrough in October, when Sofant demonstrated what it claims is the world’s first fully functioning Ka-band transmit array based on its proprietary low-power RF MEMS beamforming IC, backed by programmes with the European and UK space agencies, and is intended to support scaling operations, qualifying first commercial products and preparing early deployments in satellite, defence and advanced wireless markets, as the company strengthens its leadership with the appointment of industry veteran Will Whitehorn as chair and targets international expansion.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £58.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital Discloses Director’s Internal Share Transfer With Holding Unchanged

EMV Capital plc reported an internal share transfer by Senior Independent Director Jonathan Robinson, who moved 34,484 ordinary shares from his personal brokerage account into his Self-Invested Personal Pension for portfolio consolidation via a sale and repurchase at £0.5807 per share. The transaction leaves Robinson’s total holding unchanged at 233,737 shares, representing 0.84% of the company’s issued share capital, signalling no change in his economic interest in the firm and suggesting no direct impact on the group’s capital structure or operations beyond routine governance-related disclosure obligations.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £58.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

Wanda Health Secures £0.86 Million to Boost US Expansion

Wanda Health, a portfolio company of EMV Capital, has successfully raised £0.86 million to accelerate its operations and product development in the US healthcare market. The fundraising, led by EMV Capital Partners, will help Wanda scale its remote patient monitoring and virtual care platform, which is gaining traction due to rising demand for chronic disease management solutions. Wanda’s recent commercial success includes launching new programs and securing multi-million-dollar contracts, positioning it well in the rapidly expanding healthcare market. The appointment of Michael Steel as Chair is expected to further support Wanda’s growth and strategic partnerships.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £58.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital Issues New Shares to Directors, Boosting Market Confidence

EMV Capital plc has announced the issuance of 200,141 new ordinary shares to its directors and a PDMR in lieu of cash bonuses and fees, priced at £0.55 per share. This move reflects a strategic decision to align management interests with company performance, potentially enhancing shareholder value and market confidence. Additionally, directors have purchased a total of 31,638 shares, indicating strong internal confidence in the company’s future prospects. The new shares will be admitted to trading on AIM, increasing the total voting rights to 27,967,532, which may influence shareholder voting dynamics and interest disclosures.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £58.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital Expands Finance Leadership to Support Growth

EMV Capital plc has announced a significant expansion of its senior finance leadership team, appointing Anesh Patel as the new Group Chief Financial Officer and transitioning Stephen Crowe to the newly created role of Portfolio CFO. This strategic move reflects the company’s growth, with over £100 million in assets under management and a portfolio of more than seventy companies. The changes aim to enhance the company’s finance function by dedicating roles to group-focused and portfolio company growth, supporting EMV Capital’s continued expansion and its drive towards operational break-even.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £45.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital to Host Virtual Portfolio Showcase

EMV Capital plc announced a virtual ‘Meet the Portfolio’ event on December 1, 2025, to provide investors insights into its portfolio companies, Wanda Health and DeepTech Recycling. This event, part of EMV Capital’s ongoing investor engagement program, aims to enhance transparency and engagement with stakeholders, potentially strengthening the company’s market position by showcasing its innovative investments in remote patient monitoring and sustainable recycling technologies.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £45.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.